Tobramycin
| Clinical data | |
|---|---|
| Trade names | Nebcin, Tobrex, Tobi, others | 
| Other names | 47663, SPRC-AB01 | 
| AHFS/Drugs.com | Monograph | 
| MedlinePlus | a682660 | 
| License data | 
 | 
| Pregnancy category | 
 | 
| Routes of administration | Intravenous, intramuscular, inhalation, ophthalmic | 
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | Not bound | 
| Metabolism | Not metabolized | 
| Elimination half-life | 2–3 hrs | 
| Excretion | Exclusively via kidneys | 
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| PDB ligand | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.046.642 | 
| Chemical and physical data | |
| Formula | C18H37N5O9 | 
| Molar mass | 467.520 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
| (verify) | |
Tobramycin is an aminoglycoside antibiotic derived from Streptomyces tenebrarius that is used to treat various types of bacterial infections, particularly Gram-negative infections. It is especially effective against species of Pseudomonas.
It was patented in 1965, and approved for medical use in 1974. It is on the World Health Organization's List of Essential Medicines. In 2022, it was the 281st most commonly prescribed medication in the United States, with more than 600,000 prescriptions.